Presentation Highlighted Data Supporting Clinical Benefit of GTx-104 Compared to Orally Administered Nimodipine in the Treatment of aneurysmal Subarachnoid Hemorrhage...
PARAMUS, N.J., Sept. 19, 2025 /PRNewswire/ -- NS Pharma, Inc. announced today that the U.S. Food & Drug Administration (FDA)...
MESA, ARIZONA / ACCESS Newswire / September 19, 2025 / Medical Care Technologies Inc. (OTC PINK:MDCE), a pioneer in AI-powered...
Pending the European Commission’s final decision, nipocalimab could be the first FcRn blocker approved in both adult and adolescent gMG...
Pending the European Commission’s final decision, nipocalimab could be the first FcRn blocker approved in both adult and adolescent gMG...
Updates to McDonald Diagnostic Criteria for MS published NEW YORK, Sept. 18, 2025 /PRNewswire/ -- The McDonald Diagnostic Criteria for...
WEST PALM BEACH, Fla., Sept. 18, 2025 /PRNewswire/ -- On September 12–13, 2025, the Hilton West Palm Beach hosted the Clinical...
Research Triangle Park, N.C., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Final participant randomized to complete enrollment in Phase 1 clinical...
BOSTON, Sept. 17, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for...
Six poster presentations showcase clinical and real-world data in major depressive disorder, Alzheimer’s disease agitation, narcolepsy, and obstructive sleep apneaNEW...
BUCHAREST, Romania, Sept. 16, 2025 /PRNewswire/ -- Bucharest hosted an important visit this week, as IMPROVATE organized a high-level Israeli medical technology...
Current XanaMIA pivotal phase 2/3 trial on track for interim analysis in January 2026 and final results late 2026 with...
WILMETTE, Ill., Sept. 14, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical...
The transaction adds larsucosterol, an FDA Breakthrough Therapy for alcohol-associated hepatitis with a registrational Phase 3 clinical trial in development,...
Sanofi’s SAR402663 earns fast track designation in the US for neovascular age-related macular degeneration Designation earned for a one-time intravitreal...
BELFAST, Northern Ireland, Sept. 10, 2025 /PRNewswire/ -- Cumulus Neuroscience (Cumulus; The Company), a global digital health company focused on advancing...
NeuroKaire's blood-based screening tool, BrightKaire,™ is also expected to save more than $16 billion annually in avoidable treatment costs. KEARNY,...
NeuroKaire's blood-based screening tool, BrightKaire,™ is also expected to save more than $16 billion annually in avoidable treatment costs. KEARNY,...
Integration of PhaseV's Trial Optimizer with Bioforum's Biometric CRO Services Creates an End-to-End Solution for Smarter, Faster, and More Efficient...
Integration of PhaseV's Trial Optimizer with Bioforum's Biometric CRO Services Creates an End-to-End Solution for Smarter, Faster, and More Efficient...